EN
The Santen Pharmaceutical Co., Ltd. (TSE:4536) Interim Results Are Out And Analysts Have Published New Forecasts
Investors in Santen Pharmaceutical Co., Ltd. (TSE:4536) had a good week, as its shares rose 5.8% to close at JP¥1,894 following the release of its interim results. Results were roughly in line with estimates, with revenues of JP¥143b and statutory earnings per share of JP¥48.05. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Taking into account the latest results, the most recent consensus for Santen Pharmaceutical from nine analysts is for revenues of JP¥303.8b in 2027. If met, it would imply a credible 2.3% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to increase 3.8% to JP¥126. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥304.0b and earnings per share (EPS) of JP¥121 in 2027. So the consensus seems to have become somewhat more optimistic on Santen Pharmaceutical's earnings potential following these results.
Check out our latest analysis for Santen Pharmaceutical
The consensus price target was unchanged at JP¥2,383, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Santen Pharmaceutical, with the most bullish analyst valuing it at JP¥2,800 and the most bearish at JP¥1,900 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Santen Pharmaceutical shareholders.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Santen Pharmaceutical's growth to accelerate, with the forecast 4.6% annualised growth to the end of 2027 ranking favourably alongside historical growth of 2.5% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.5% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Santen Pharmaceutical to grow faster than the wider industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Santen Pharmaceutical's earnings potential next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at JP¥2,383, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Santen Pharmaceutical going out to 2029, and you can see them free on our platform here..
You can also see our analysis of Santen Pharmaceutical's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.